

NB: this is a summary translation of the press release original drafted in Japanese for the disclosure required in compliance with the TSE regulations.

July 26, 2021

Oncolys BioPharma Inc.

Announcement of the effect of OBP-2011 against Indian and South African variants of SARS-CoV-2 virus

Tokyo, Japan, July 26, 2021 -- Oncolys BioPharma Inc. (Head Office: Minato-ku, Tokyo; (JPX:4588), "Oncolys") today announced that its candidate for Covid -19 therapeutic agent (OBP-2011) showed effectiveness against Indian and South African variants of SARS-CoV-2 in vitro experiment.

OBP-2011 showed the same activity as the wild-type strain against the Indian variant "Delta," which is said to be particularly infectious among mutant coronaviruses in vitro experiment. In addition to the UK "Alpha" and the Brazilian "Gamma" variants, the comparable activity was confirmed for the South African variant "Beta".

As a result, OBP-2011 was confirmed to be effective against all VOC (Variants of Concern: UK, Brazilian, Indian, South African variants) designated by the World Health Organization (WHO) as VOC and also found to show an effect for SRAS (Severe Acute Respiratory Syndrome) and MERS (Middle East Respiratory Syndrome).

Oncolys continues to make progress to complete GMP manufacturing and preclinical study in the first half in 2022.

Ends

###

About Oncolys BioPharma Inc.

Oncolys BioPharma develops not only novel therapeutics for cancer and serious infectious diseases, but diagnostic products using gene modified viral technologies and aims to contribute to fulfill unmet medical needs for those diseases.

Especially in oncology area, we utilize technology platform for oncolytic virus and develop Telomelysin and its next-generations for cancer treatment and TelomeScan for early detection of cancer and recurrence monitoring after surgery. We have established broad range of product pipeline to cover early detection of cancer, early treatment of local cancer, post-operative examination, and treatment of metastatic cancer. For more information, please visit <http://www.oncolys.com/en/>

Enquiries:

Oncolys BioPharma Inc.

Email: oncolys_information@oncolys.com